Phase I/Ii Trial Of Glasdegib In Patients With Primary Or Secondary Myelofibrosis

Phase I/II Trial of Glasdegib in Patients with Primary or Secondary Myelofibrosis

Phase I/II Trial of Glasdegib in Patients with Primary or Secondary Myelofibrosis

MPNUniversity .tv

Aaron Gerds, MD: Glasdegib and New Directions in Myelofibrosis Treatment

American Society of Hematology

Glasdegib for AML

Primary vs Secondary Myelofibrosis | What’s the Difference?

Patient Empowerment Network

Glasdegib therapy for MDS and AML

VJHemOnc – Video Journal of Hematology & HemOnc

Phase II trial of KER-050 in patients with myelofibrosis

VJHemOnc – Video Journal of Hematology & HemOnc

Dr. Schiller on Venetoclax and Glasdegib in AML

Primary vs. Secondary Myelofibrosis: What’s the Difference?

Patient Empowerment Network

Outcomes of patients with accelerated-phase myelofibrosis after reduced-intensity HSCT

VJHemOnc – Video Journal of Hematology & HemOnc

Acute myeloid leukemia,High-risk myelodysplastic syndrome,Glasdegib, a Hedgehog Pathway Inhibitor,in

Alexandros G. Sfakianakis

Smoothening the spines: hedgehog signaling inhibitor glasdegib combinations for AML

VJHemOnc – Video Journal of Hematology & HemOnc

Results of Phase II trial of olutasidenib in patients with R/R mIDH1 AML

VJHemOnc – Video Journal of Hematology & HemOnc

MPN Clinical Trial Updates for Patients

MPN Advocacy & Education International

Treating Intermediate/High-Risk Primary Myelofibrosis

Treatment of Primary Myelofibrosis

Efficacy of navitoclax with ruxolitinib in myelofibrosis patients

VJHemOnc – Video Journal of Hematology & HemOnc

Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomas

VJHemOnc – Video Journal of Hematology & HemOnc

Preview of our new video tutorial “How to Diagnose Primary Myelofibrosis”

Society for Hematopathology SH

Safety and efficacy of glasdegib for R/R AML

VJHemOnc – Video Journal of Hematology & HemOnc